Mer­ck steps in­to NASH space with ear­ly da­ta for its GLP-1/glucagon re­cep­tor co-ag­o­nist

Mer­ck is teas­ing da­ta for efinopeg­du­tide, a GLP-1/glucagon re­cep­tor co-ag­o­nist, in non­al­co­holic steato­hep­ati­tis (NASH) and how it com­pares to No­vo Nordisk’s semaglu­tide, with plans to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.